{"id":"NCT01305655","sponsor":"Nordic Society for Pediatric Hematology and Oncology","briefTitle":"Glucarpidase Effect on Severe Delayed HDM-clearance in Children Treated With High-dose Mtx in ALL","officialTitle":"Glucarpidase (CPG2) Effect on Severe Delayed Methotrexate-clearance in Children Treated With High-dose Methotrexate in Acute Lymphoblastic Leukemia (ALL)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-07","primaryCompletion":"2014-12","completion":"2014-12","firstPosted":"2011-03-01","resultsPosted":"2017-02-03","lastUpdate":"2018-09-28"},"enrollment":47,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Acute Lymphoblastic Leukemia (ALL)"],"interventions":[{"type":"DRUG","name":"Glucarpidase","otherNames":["VORAXAZEÂ®"]}],"arms":[{"label":"Glucarpidase arm","type":"EXPERIMENTAL"}],"summary":"Early intervention in children and adolescents who experience delayed MTX-clearance and renal dysfunction in ALL treatments with the enzyme Glucarpidase which rapidly hydrolyses MTX to non-toxic metabolites to avoid life threatening complications.","primaryOutcome":{"measure":"Number of Participants With Adverse Event to HD-MTX Treatment in NOPHO ALL-2008 as a Measure of Toxic Mtx Concentrations in Blood, Nephrotoxicity, Hepatotoxicity, Mucositis, MTX Elimination Time and Permanent Kidney Damage.","timeFrame":"6 years 6 months","effectByArm":[{"arm":"Glucarpidase Arm","deltaMin":47,"sd":null}],"pValues":[]},"eligibility":{"minAge":"1 Year","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":5,"countries":["Denmark","Finland","Iceland","Norway","Sweden"]},"refs":{"pmids":["27966809"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":47},"commonTop":[]}}